Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company pioneering novel therapies for multidrug-resistant bacterial infections and rare diseases. This page serves as the definitive source for verified news and official updates on SPRO's research advancements, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find timely updates on key programs including tebipenem HBr (oral carbapenem antibiotic), SPR206 (IV polymyxin), and other pipeline developments. The curated news collection covers clinical trial results, FDA communications, partnership announcements, and financial disclosures.
All content is rigorously verified to ensure accuracy and relevance for stakeholders monitoring antibiotic innovation. Bookmark this page for direct access to SPRO's latest developments in addressing critical unmet medical needs through advanced therapeutic candidates.
Rhea-AI Summary
Spero Therapeutics, Inc. (SPRO) will host a conference call to report Q4 and full year financial results, updating on its business and pipeline. The call is on March 13, 2024, at 4:30 p.m. ET. SPRO focuses on rare diseases and MDR bacterial infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
-
Rhea-AI Summary
Spero Therapeutics, Inc. (SPRO) receives FDA clearance for Phase 2 study of SPR206, a novel antibiotic for HABP/VABP caused by MDR Gram-negative bacterial infections. The drug aims to address unmet medical needs in treating serious infections. The study will evaluate safety, efficacy, and pharmacokinetics in combination with select antibiotics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
-
Rhea-AI Summary
Spero Therapeutics, Inc. (SPRO) announced that its President and CEO will present at the Cowen 44th Annual Healthcare Conference. The company focuses on developing therapies for rare diseases and MDR bacterial infections. The presentation is scheduled for March 4, 2024, with webcast details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
Rhea-AI Summary
Spero Therapeutics, Inc. (Nasdaq: SPRO) has announced the approval of 50,000 restricted stock unit awards (RSUs) for a new employee under the 2019 Inducement Equity Incentive Plan. The RSUs will vest in four equal annual installments beginning on February 1, 2025, subject to the employee's continued employment with Spero on such vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
-
Rhea-AI Summary
Spero Therapeutics Inc. (SPRO) provided a corporate update highlighting its recent accomplishments and anticipated milestones for 2024. The company expects to provide Phase 2a topline proof-of-concept data from its lead program SPR720 in NTM-PD patients in 2H 2024. It has initiated dosing in the PIVOT-PO Phase 3 trial for tebipenem HBr in cUTI patients, with a target enrollment of approximately 2,648 patients, expected to be completed in 2H of 2025. Spero is entitled to receive $95 million in development milestones, payable over two years, as part of the GSK license agreement. The company's preliminary cash balance as of December 31, 2023, was approximately $76.3 million, with a cash runway guidance into late 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
-
Rhea-AI Summary
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the first patient, first visit for PIVOT-PO, a global pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). Spero is entitled to receive $95 million in development milestone payments from GSK, payable in four equal installments over two years. The trial is designed to enroll approximately 2,648 patients, with randomization stratified by age, baseline diagnosis, and the presence or absence of urinary tract instrumentation. Positive results from PIVOT-PO could support approval of tebipenem HBr as a treatment for cUTI, including pyelonephritis, for a limited use indication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
News
Rhea-AI Summary
Spero Therapeutics, Inc. (Nasdaq: SPRO) has announced a Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr. The trial is expected to begin with First Patient, First Visit in 4Q 2023. The company also provided a business update and third-quarter financial results, highlighting substantial progress across its late-stage programs throughout 2023 and anticipated milestones before year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
-
Rhea-AI Summary
Spero Therapeutics, Inc. (Nasdaq: SPRO) will host a conference call and live audio webcast on November 13, 2023, at 4:30 p.m. ET to report its third quarter 2023 financial results and provide an update on its business and pipeline. The call can be accessed by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international) with conference ID 13741831, or through the company's website. The webcast will be available on the website for 30 days after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
-
Rhea-AI Summary
Spero Therapeutics, a biopharmaceutical company focused on rare diseases and MDR bacterial infections, announced that its CEO will be attending two upcoming conferences: the Truist Securities BioPharma Symposium on November 8-9, 2023, and the 6th Annual Evercore ISI HealthCONx Conference on November 28-30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
Spero Therapeutics, Inc. has appointed Esther Rajavelu as Chief Financial Officer and Chief Business Officer. Rajavelu brings over two decades of experience in the life sciences sector and will play a key role in the company's success as they advance their pipeline and prepare for upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
Spero Therapeuti
Nasdaq:SPRO
SPRO Rankings
SPRO Stock Data
42.16M
41.52M
24.47%
24.89%
0.78%
Biotechnology
Pharmaceutical Preparations
United States
CAMBRIDGE